The table below shows Ultragenyx Pharmaceutical Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$673.00M
$560.00M
$434.00M
$363.33M
$351.41M
$271.03M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$750.00M
$698.00M
$648.00M
$705.79M
$497.15M
$412.08M
SG&A
RARE annual revenue (10-K history)
Ultragenyx Pharmaceutical Inc. reported annual revenue of $673.00M for fiscal year 2025. That is up 20.2% from $560.00M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.00K (FY 2016) to $673.00M. Figures come from the company's audited annual reports as filed with the SEC.